Besifloxacin Ophthalmic Suspension 0.6% in the Treatment of Bacterial Keratitis: A Retrospective Safety Surveillance Study
- 1 March 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 31 (2) , 114-121
Abstract
The objective of this study was to collect and evaluate retrospective safety information about the use of besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial keratitis. This was a retrospective, postmarketing surveillance study conducted at 10 clinical centers in the United States. The study population included 142 patients treated with besifloxacin ophthalmic suspension 0.6% for bacterial keratitis in one or both eyes. For perspective, data on 85 patients treated at these centers with moxifloxacin ophthalmic solution 0.5% for bacterial keratitis were also included. The analysis was designed to measure the types and rates of adverse events (AEs) reported during the treatment of bacterial keratitis with besifloxacin ophthalmic suspension 0.6%. Other treatment outcomes of interest included the development of corneal scarring and corneal neovascularization, measured or presumed bacterial eradication, ending visual acuity, and duration of pain before and after treatment. There was one reported AE of mild superficial punctate keratitis in a patient using besifloxacin ophthalmic suspension 0.6%. The difference in AE frequencies between groups was not significant (P>0.999). Additional treatment outcomes were similar for both groups. Limitations of this report include the retrospective nature of the study. These retrospective data suggest that besifloxacin ophthalmic suspension 0.6% was well tolerated when included in the treatment of bacterial keratitis; no serious AEs were reported. A prospective clinical trial is needed to better isolate the contribution of besifloxacin to the therapeutic outcome and to confirm these observations.Keywords
This publication has 37 references indexed in Scilit:
- Pharmacological treatment for infectious corneal ulcersExpert Opinion on Pharmacotherapy, 2013
- Infectious keratitisCurrent Opinion in Infectious Diseases, 2007
- Microbial KeratitisOphthalmology, 2006
- Infections following laser in situ keratomileusis: An Integration of the Published LiteratureSurvey of Ophthalmology, 2004
- Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 casesBritish Journal of Ophthalmology, 2003
- Study of the First Contact Management Profile of Cases of Infectious Keratitis: A Hospital-Based StudyCornea, 2000
- Risk factors in microbial keratitis leading to penetrating keratoplastyOphthalmology, 1999
- The Role of Smears, Cultures, and Antibiotic Sensitivity Testing in the Management of Suspected Infectious KeratitisOphthalmology, 1996
- Efficacy of Ofloxacin vs Cefazolin and Tobramycin in the Therapy for Bacterial KeratitisArchives of Ophthalmology (1950), 1995
- 0.3% Ciprofloxacin Ophthalmic Ointment in the Treatment of Bacterial KeratitisArchives of Ophthalmology (1950), 1993